Incyte CEO sees $2B Vega deal aiding a post-Jakafi futurenews2026-06-08T19:01:18+00:00June 8th, 2026|Endpoints News|
Treeline to go public via reverse merger with Standard BioToolsnews2026-06-08T15:16:35+00:00June 8th, 2026|Endpoints News|
J&J makes $1B move for Firefly Bio, Carolyn Bertozzi’s twist on ADCs in KRAS fieldnews2026-06-08T14:53:00+00:00June 8th, 2026|Endpoints News|
Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront dealnews2026-06-08T11:03:56+00:00June 8th, 2026|Endpoints News|
Nurix to work with Roche on BTK degrader in pact worth up to $2.3Bnews2026-06-08T10:57:19+00:00June 8th, 2026|Endpoints News|
Parabilis Medicines charts $413M IPO to back peptide pipelinenews2026-06-04T13:04:21+00:00June 4th, 2026|Endpoints News|
Alnylam to pay $30M upfront to AI startup Inceptive in RNA R&D dealnews2026-06-03T20:45:47+00:00June 3rd, 2026|Endpoints News|
Regeneron doubles down on CytomX after other pharmas walked awaynews2026-06-03T14:56:16+00:00June 3rd, 2026|Endpoints News|
Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseasesnews2026-06-03T11:00:46+00:00June 3rd, 2026|Endpoints News|
Travere pays Everest $112M upfront to grow rare kidney disease pipelinenews2026-06-02T13:55:55+00:00June 2nd, 2026|Endpoints News|
